- Advertisement -
That is lower than rival jabs developed in the West by Pfizer-BioNTech and Moderna — with 95 and 94 percent rates respectively — but still a game-changer for China. Chen Shifei, deputy commissioner of the National Medical Products Administration, on Thursday told reporters his agency had granted a “conditional listing” to Sinopharm’s vaccine.
A conditional listing helps hustle emergency drugs to market in cases when clinical trials are yet to meet normal standards but indicate they will work.vaccine are bigger than the known and potential risks,” Chen added.The listing allows the government to “extend vaccination to high-risk groups, those susceptible to a severe viralBut China faces the unprecedented challenge of getting“The general view is you have to vaccinate 60 to 70 percent to establish universal protection,” Zeng added.
China has also pledged to swiftly share its vaccines with lesser developed countries at a “fair price”, as